Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

Smoking has been shown to have significant associations with peripheral artery disease, CHD and stroke, with the strongest link seen for PAD, according to a study published in the Journal of the American College of Cardiology.

The availability of more effective and less toxic anticancer agents has made it increasingly difficult for clinicians to discern when to discontinue treatment for patients with advanced solid tumors.

Click here to read the Cover Story, “New treatments, new outcomes for refractory thyroid cancer.”

Bayer has invested $215 million in Century Therapeutics, a biotech startup looking to break into the oncology cell therapy market with a platform based on allogeneic induced pluripotent stem cells.

With approximately 73,820 diagnoses and 14,770 deaths expected this year in the U.S., renal cell carcinoma remains a cancer in need of new treatment options.

CHICAGO — The MONALEESA-7 trial demonstrated that adding the CDK4/6 inhibitor ribociclib (Kisqali, Novartis) to endocrine therapy improved OS in patients with premenopausal or perimenopausal, metastatic, hormone receptor-positive breast cancer, Aditya Bardia, MD, MPH, medical oncologist at Massachusetts General Hospital Cancer Center and Harvard Medical School, told HemOnc Today at the ASCO Annual Meeting.

CHICAGO — The combination of ribociclib, everolimus and exemestane conferred clinical benefit and appeared tolerable among patients with endocrine therapy-refractory, hormone receptor-positive, HER2-negative advanced breast cancer that progressed on a CDK4/6 inhibitor, according to data from the TRINITI-1 trial presented at ASCO Annual Meeting.

SAN FRANCISCO — A novel mapping system to identify drivers of atrial fibrillation beyond the pulmonary vein was associated with successful AF ablation at 9 months, according to the RADAR study presented at the Heart Rhythm Society Annual Scientific Sessions.

LAS VEGAS — In this video exclusive, Ignacio Inglessis, MD, medical director of the structural heart disease program at the Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the ideas behind the REDUCE postapproval study of patent foramen ovale closure with the Gore Cardioform device (W.L. Gore and Associates) as a strategy for secondary stroke prevention.